Peptide headlines, one question at a time

Read the exact entry

Keep the whole set together

1. Appendix A membership.
2. Appendix B identity and route limits.
3. Section 510 registered facility; valid certificate of analysis (COA): Appendix B identity, purity, potency and contaminant testing.
4. Original manufacturer: section 510 registration, CGMP/FD&C compliance, physical address on COA; registered intermediaries document manufacturer/COA validation.
5. Report products, serious adverse events regardless of causation, and quality issues to FDA and compounding/destination States; use MedWatch for events/quality; label reporting procedures. Product reports identify ingredient/strength per unit, manufacturer/facility identifier, form/route.
6. Label: “This is a compounded drug product. Not for resale.”
7. Only one active ingredient, from Appendix A.
8. Oral: document adequate human bioavailability of the supplied formulation.
9. Co-packaged/containing delivery device: only an FDA 510(k)-cleared syringe.
10. Remaining FD&C rules, sanitary conditions and patient-specific prescriptions.

^[1]

Ask what the evidence is attached to

FDA explains that compounded drugs are not approved products or approved generics; they lack the same premarket review of safety, effectiveness and quality. FDA also distinguishes finished drugs compounded in accordance with 503A, which are exempt from current good manufacturing practice (CGMP) requirements, from outsourcing-facility drugs, which are subject to them. ^[4]

The original manufacturer's CGMP duty concerns the bulk ingredient. FDA's finished-product distinction answers a separate question; neither establishes approval of a medicine. ^[1][4]

For example, imagine being handed a certificate and told it settles your concern. Write the concern down first: is it about identity, an expected benefit or help after a problem? Then ask the person presenting the certificate to show the connection. A missing explanation is a useful next question, not a gap you need to fill yourself.

Read a plan as a plan

Hims & Hers announced a Peptides+ preview and waitlist on October 29. Planned therapies include sermorelin, glutathione, B12, NAD+ and L-carnitine—a mixed menu, not five peptides. BPC-157 and TB-500 would follow when allowable. The announcement does not verify current dispensing, prices, eligibility in your location or clinical benefit. ^[3]

Keep the company's verb when taking notes: plans, offers, delivered. Those words describe different stages. If a page invites you to register interest, your next question is when and how the actual care terms will be supplied. You can request that information without treating the invitation as a treatment decision.

Keep your reading dates visible

Our existing references retain their earlier clinical and source dates. This notebook adds policy context; it does not recheck every older conclusion, inspect a pharmacy or certify your prescription. The same applies to the compounded-semaglutide guide: a new reading link is not a new eligibility finding.

For a useful appointment note, bring the exact offer you are considering and circle the sentence you cannot connect to its evidence. Ask who can answer it and what written information would resolve it. That gives the conversation a starting point more specific than asking whether peptides, as a whole, are good or bad.

Reader questions